Savara Inc - Common Stock, par value $0.001 per share (SVRA)

CUSIP: 805111101

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 7 signals
Share change
+10,582,442
Put/Call ratio
38%
SEC-reported price per share
$5.46
Number of holders
185
Value change
+$54,962,865
Number of buys
115
Open additional details 1 more signal available
Number of sells
60
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
210,922,101

Security key

805111101

Report period

Q1 2026

Institutions

185

Top holders

10

Ownership snapshot

Top reported holders of SVRA - Savara Inc - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Growth Equity Opportuniti...
Disclosed value leader
Venrock Healthcare Capita...
Comparable rows
15/15
Latest evidence
16 Feb 2026
3/4/5 13D/G 13F Lead comparable stake: 12% 13D/G row: Growth Equity Opportunities 17, LLC Showing 1-6 of 15 holder rows.

Quick read

Growth Equity Opportunities 17, LLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Growth Equity Opportunities 17, LLC's linked filing trail.
Comparable ownership Top 5
Growth Equity Opportunities 17, LLC 12%
Bain Capital Life Sciences Fund I... 10%
Venrock Healthcare Capital Partne... 9.9%
Farallon Capital Partners, L.P. 6.9%
James E. Flynn 6.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Growth Equity Opportunities 17, LLC
3/4/5 13D/G
10%+ Owner
12%
from 13D/G
$108,897,125
24,471,264 shares
17 Jul 2023
Bain Capital Life Sciences Fund II, L.P.
13D/G
10%
$55,969,975
17,600,621 shares
$0 25 Mar 2025
Venrock Healthcare Capital Partners III, L.P.
13D/G
9.9%
$123,617,225
20,881,288 shares
+$48,545,450 31 Dec 2025
Farallon Capital Partners, L.P.
13D/G
Dapice Joshua J.
6.9%
$90,445,500
15,000,000 shares
-$19,831,599 31 Dec 2025
James E. Flynn
13D/G
Deerfield Mgmt, L.P.
6.7%
$48,441,330
13,569,000 shares
$0 30 Oct 2025
TCG Crossover GP I, LLC
13D/G
6.1%
$73,184,254
12,362,205 shares
$0 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
185
Shares
212,258,088
Rows available
185
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders
185
Q1 2026 holders
185
Holder diff
0
Investor Q1 2026 Shares Q1 2026 Shares Share Diff Share Chg % Q1 2026 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .